Related Experiment Video

Updated: Feb 26, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K

Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib

Dorota Kwapisz1

  • 1Specialist Outpatient Clinic, Warsaw, Poland. dmkwapisz@gmail.com.

Breast Cancer Research and Treatment
|July 26, 2017
PubMed
Abstract

Insights

Selective CDK4/6 inhibitors show efficacy in treating metastatic breast cancer. These oral medications offer a manageable safety profile and are a vital treatment option for patients.

Area of Science:

  • Oncology
  • Cell Cycle Regulation
  • Pharmacology

Background:

  • The cyclin D-CDK4/6-INK4-Rb pathway is critical for cell cycle progression.
  • Dysregulation of this pathway contributes to endocrine therapy resistance in breast cancer.
  • Selective CDK4/6 inhibitors induce cell cycle arrest in Rb-competent cells.

Purpose of the Study:

  • To review preclinical and clinical data on CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) in breast cancer.
  • To discuss ongoing clinical trials involving these agents.
  • To highlight their role in overcoming endocrine therapy resistance.

Main Methods:

  • Literature search using PubMed.
  • Inclusion of data from international oncology meetings.
  • Inclusion of data from clinicaltrials.gov.

Main Results:

  • Phase III studies demonstrated efficacy of oral CDK4/6 inhibitors with endocrine therapy in metastatic breast cancer.
  • Palbociclib and ribociclib are FDA-approved; abemaciclib is in development.
  • Ongoing trials investigate these agents in early-stage breast cancer and other settings, including triple-negative breast cancer.

Conclusions:

  • CDK4/6 inhibitors have shown significant activity in ER-positive, HER2-negative metastatic breast cancer.
  • This class of agents represents an important treatment option due to efficacy, manageable toxicity, and oral administration.
  • Further development is ongoing for CDK4/6 inhibitors in various breast cancer contexts.
Keywords:
AbemaciclibBreast cancerCDK4/6 inhibitorsPalbociclibRibociclib

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
7.0K
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
136.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K